Italfarmaco and JCR Pharmaceuticals signed an exclusive licensing agreement on October 2, 2026, to develop and commercialize the experimental enzyme replacement therapy JR-141 in the United States, Europe, and Latin America. The therapy, also known as pabinafusp alfa, is currently undergoing Phase III clinical evaluation (NCT04573023) for treating Hunter syndrome, which is formally classified as mucopolysaccharidosis type II or MPS II.
Italfarmaco and JCR Pharmaceuticals plan global regulatory submissions
The two partner companies plan to submit JR-141 for regulatory approval to several major health authorities, including the United States Food and Drug Administration, the European Medicines Agency, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, and Brazil’s Brazilian Health Regulatory Agency. Following official market authorizations, Italfarmaco will handle the commercialization and distribution of the therapy within the approved territories. Meanwhile, JCR Pharmaceuticals will retain manufacturing responsibilities for the drug supply upon receiving marketing authorizations. In exchange for these rights, JCR will receive upfront payments, milestone fees, royalties, and product supply revenues.
J-Brain Cargo technology carries enzymes across blood-brain barrier
JR-141 functions as a next-generation recombinant fusion protein designed to address both somatic and neurological symptoms of Hunter syndrome. The molecule consists of an antibody targeting the human transferrin receptor fused to iduronate-2-sulfatase, which is the specific enzyme missing or dysfunctional in patients with the genetic condition. To reach the central nervous system, the therapy utilizes JCR’s proprietary J-Brain Cargo technology. This transport system is engineered to carry the therapeutic enzyme across the blood-brain barrier directly into the brain, combating the progressive cognitive decline that standard enzyme replacement therapies fail to treat.
Corporate Collaboration History
This agreement expands an existing partnership between the two pharmaceutical companies. In December 2025, Italfarmaco and JCR Pharmaceuticals established an exclusive licensing agreement for the commercialization of givinostat in Japan as a treatment for Duchenne muscular dystrophy, alongside a broader strategic partnership focused on rare diseases. Francesco Di Marco, Chief Executive Officer of Italfarmaco Group, stated that the new agreement reflects a shared commitment to developing innovative therapies for rare and genetic conditions. Hiroyuki Sonoda, president and Chief Scientific Officer of JCR Pharmaceuticals, added that the partnership aims to make JR-141 available to patients outside of Japan as quickly as possible.
Hunter syndrome affects thousands of individuals worldwide
Hunter syndrome is an X-linked recessive lysosomal storage disorder caused by a deficiency of the iduronate-2-sulfatase enzyme. According to data from JCR Pharmaceuticals, the condition affects approximately 2,000 to 3,000 individuals worldwide. The disease manifests through both physical (somatic) and neurological symptoms. While the molecule pabinafusp alfa has already been approved and commercialized in Japan since 2021 and received approval in the United Arab Emirates in 2026, regulators in the US, Europe, and Latin America have not yet granted marketing authorization for the therapy.
Frequently Asked Questions About the Italfarmaco and JCR Agreement
What is the primary function of JR-141 in treating Hunter syndrome?
JR-141 delivers iduronate-2-sulfatase across the blood-brain barrier using J-Brain Cargo technology to treat both somatic and neuronopathic symptoms of MPS II.
Which regulatory agencies are targeted for marketing authorization submissions?
The companies intend to seek approvals from the US FDA, the European EMA, the UK MHRA, and Brazil’s Anvisa.
How does this agreement build upon previous business between the two companies?
The deal expands on a December 2025 agreement that granted Italfarmaco rights to commercialize givinostat for Duchenne muscular dystrophy in Japan.